Glycemic Control by Treatment Modalities: National Registry-Based Population Data in Children and Adolescents with Type 1 Diabetes
Authors:
- Zdenek ŠumnikZŠZdenek Šumnik
- Marketa PavlíkováMPMarketa Pavlíková
- Vit NeumanVNVit Neuman
- Lenka PetruželkováLPLenka Petruželková
- Petra KonečnáPKPetra Konečná
- Petra VenháčováPVPetra Venháčová
- Jaroslav ŠkvorJŠJaroslav Škvor
- Renata PomahačováRPRenata Pomahačová
- David NeumannDNDavid Neumann
- Jan VosáhloJVJan Vosáhlo
- Jiri StrnadelJSJiri Strnadel
- Kamila KocourkováKKKamila Kocourková
Open Access
- 26 April 2023
- journal article
- research article
- Published by S. Karger AG in Hormone Research in Paediatrics
- Vol. 97 (1) , 70-79
Abstract
Introduction: The aim of the study was to assess the differences in key parameters of type 1 diabetes (T1D) control associated with treatment and monitoring modalities including newly introduced hybrid closed-loop (HCL) algorithm in children and adolescents with T1D (CwD) using the data from the population-wide pediatric diabetes registry ČENDA. Methods: CwD younger than 19 years with T1D duration >1 year were included and divided according to the treatment modality and type of CGM used: multiple daily injection (MDI), insulin pump without (CSII) and with HCL function, intermittently scanned continuous glucose monitoring (isCGM), real-time CGM (rtCGM), and intermittent or no CGM (noCGM). HbA1c, times in glycemic ranges, and glucose risk index (GRI) were compared between the groups. Results: Data of a total of 3,251 children (mean age 13.4 ± 3.8 years) were analyzed. 2,187 (67.3%) were treated with MDI, 1,064 (32.7%) with insulin pump, 585/1,064 (55%) with HCL. The HCL users achieved the highest median TIR 75.4% (IQR 6.3) and lowest GRI 29.1 (7.8), both p < 0.001 compared to other groups, followed by MDI rtCGM and CSII groups with TIR 68.8% (IQR 9.0) and 69.0% (7.5), GRI 38.8 (12.5) and 40.1 (8.5), respectively (nonsignificant to each other). These three groups did not significantly differ in their HbA1c medians (51.8 [IQR 4.5], 50.7 [4.5], and 52.7 [5.7] mmol/mol, respectively). NoCGM groups had the highest HbA1c and GRI and lowest TIR regardless of the treatment modality. Conclusion: This population-based study shows that the HCL technology is superior to other treatment modalities in CGM-derived parameters and should be considered as a treatment of choice in all CwD fulfilling the indication criteria.Keywords
This publication has 29 references indexed in Scilit:
- Real-time CGM Is Superior to Flash Glucose Monitoring for Glucose Control in Type 1 Diabetes: The CORRIDA Randomized Controlled TrialDiabetes Care, 2020
- A Randomized Trial of Closed-Loop Control in Children with Type 1 DiabetesNew England Journal of Medicine, 2020
- An Observational Study of the Equivalence of Age and Duration of Diabetes to Glycemic Control Relative to the Risk of Complications in the Combined Cohorts of the DCCT/EDIC StudyDiabetes Care, 2020
- Time In Range in Children with Type 1 Diabetes Using Treatment Strategies Based on Nonautomated Insulin Delivery Systems in the Real WorldDiabetes Technology & Therapeutics, 2020
- Five years of improving diabetes control in Czech children after the establishment of the population‐based childhood diabetes register ČENDAPediatric Diabetes, 2019
- The Transatlantic HbA1c gap: differences in glycaemic control across the lifespan between people included in the US T1D Exchange Registry and those included in the German/Austrian DPV registryDiabetic Medicine, 2019
- Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in RangeDiabetes Care, 2019
- Optimal Sampling Duration for Continuous Glucose Monitoring to Determine Long-Term Glycemic ControlDiabetes Technology & Therapeutics, 2018
- Comparison of Different Treatment Modalities for Type 1 Diabetes, Including Sensor-Augmented Insulin Regimens, in 52 Weeks of Follow-Up: A COMISAIR StudyDiabetes Technology & Therapeutics, 2016
- Nocturnal Glucose Control with an Artificial Pancreas at a Diabetes CampNew England Journal of Medicine, 2013